Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 14  •  04:00PM ET
28.55
Dollar change
+0.68
Percentage change
2.44
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y24.33% Total Holdings65 Perf Week2.18%
SponsorBlackrock (iShares) ETF Type Tagsequity Return% 3Y3.72% AUM139.87M Perf Month8.10%
Fund Family Bond Type Tagshealthcare Return% 5Y-9.37% NAV/sh Perf Quarter17.78%
IndexNYSE FactSet Global Genomics and Immuno... Average Maturity Tagsgenomics Return% 10Y 52W High28.10 1.60% Perf Half Y33.60%
Index Weighting Commodity Type Tagspharmaceutical Return% SI 52W Low17.26 65.41% Perf YTD9.01%
Active/Passive Quant Type Tagsinnovation Flows% 1M0.00% Volatility1.53% 1.51% Perf Year30.07%
Dividend TTM0.31 (1.08%) ESG Type Tags- Flows% 3M0.02% ATR (14)0.50 Perf 3Y12.36%
Dividend Ex-DateDec 16, 2025 Dividend Type Sector/Theme Flows% YTD0.00% RSI (14)68.52 Perf 5Y-42.68%
Dividend Gr. 3/5Y31.32% 20.75% Structure Type Region Flows% 1Y Beta1.03 Perf 10Y-
Expense0.47% Growth/Value SMA206.32% Flows% 3Y Rel Volume0.51 Prev Close27.87
Inverse/Leveraged Market Cap SMA507.87% Flows% 5Y Avg Volume30.66K Price28.55
IPOJun 13, 2019 Option/ShortYes / Yes SMA20024.75% Trades Volume16,495 Change2.44%
Jan-09-26 10:00AM
May-02-25 03:25AM
Apr-30-25 04:35AM
04:33AM
Apr-23-25 05:45AM
11:28AM Loading…
Apr-20-25 11:28AM
Apr-18-25 01:40PM
Apr-04-25 08:30AM
Apr-02-25 07:00AM
Apr-01-25 05:40AM
Mar-28-25 06:05AM
Mar-20-25 04:32PM
Sep-09-22 01:45PM
Mar-30-22 01:30PM
Feb-25-22 09:59PM
10:15AM Loading…
Dec-06-21 10:15AM
Oct-21-21 10:15AM
May-18-20 03:42PM
10:51AM
Dec-23-19 12:00PM
Dec-18-19 01:41PM
Nov-25-19 06:55PM
Nov-21-19 12:56PM
Nov-04-19 01:00PM
Oct-23-19 10:10AM
Sep-06-19 03:07PM
Sep-04-19 03:18PM
iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.